Evommune (EVMN) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evommune is the larger company by market cap ($225.7 million vs $218.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | TRDA |
|---|---|---|
| Share price | $6.22 | $5.61 |
| Market cap | $225.74M | $218.43M |
| 1-day change | -5.90% | +3.51% |
| YTD return | -63.67% | -45.43% |
| 1-year return | — | -4.10% |
| EPS (TTM) | $-3.75 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $16.45 |
| 52-week low | $6.08 | $5.15 |
| Distance from 52-week high | -81.27% | -65.90% |
| Analyst consensus | buy | none |
| Avg. price target upside | +287.94% | +238.68% |
| Average volume | 675.52K | 362.82K |
| Shares outstanding | 36.29M | 38.94M |
| Employees | 48 | 152 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Healthcare · Biotechnology · 48 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Healthcare · Biotechnology · 152 employees
EVMN vs TRDA FAQ
Which is bigger, Evommune or Entrada Therapeutics?
Evommune (EVMN) is larger, with a market capitalization of $225.74M compared with $218.43M for Entrada Therapeutics (TRDA).
Are Evommune and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.